Progesterone Supplement and Luteal Phase Deficiency in Unifollicular Intrauterine Insemination Cycles by Bakay, Kadir et al.
Journal of Clinical and Analytical Medicine  | 
rA a l
þ
a
t
n
ý
i
r
j
m
i r
a
O
O
h
r
c
i
r
g
a
in
e
a
s
le  R
1
Kadir Bakay, Fatih Aytekin, Nilufer Yigit Celik
Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Alanya, Antalya, Turkey
Intrauterin İnseminasyonda Progesteron Etkisi / Progesterone Supplement in Intrauterine Insemination
Progesterone Supplement and Luteal Phase Deficiency in 
Unifollicular Intrauterine Insemination Cycles
Unifoliküler İntrauterin İnseminasyon Sikluslarında
 Luteal Faz Defekti ve Progesteron Desteği
DOI: 10.4328/JCAM.2321  Received: 04.02.2014 Accepted: 13.03.2014 Published Online: 15.03.2014
Corresponding Author: Kadir Bakay, Baskent University Alanya Hospital, 07400, Alanya, Antalya, Turkey.
GSM: +905308265868 E-Mail: drkadirbakay@gmail.com
Özet
Amaç: Intrauterin inseminasyon, diğer yardımcı üreme teknikleriyle karşılaş-
tırıldığında, basit olması ve düşük maliyeti nedeniyle sıklıkla kulanılmaktadır.
Mevcut araştırmada intrauterin inseminasyonda progesteron desteğinin fay-
dasını ve luteal faz defektinin unifoliküler sikluslarda da görülebileceğini vur-
gulamayı amaçladık. Gereç ve Yöntem: Aralık 2011 ve Aralık 2012 arasında 
kliniğimizde sebebi belirlenemeyen infertilite tanısı alan ve intra uterin inse-
minasyon planlanan 278 hasta prospektif randomize kontrollü araştırmaya 
dahil edildi. Bulgular: Gebelik yakalama ve devam ettirme oranları açısından 
her iki grup karşılaştırıldığında progesteron destek tedavisi istatistiksel ola-
rak anlamlı bulundu; (p< 0.05), %33.66’ya karşı %12.22. Tartışma: Progeste-
ron desteği, luteal faz defekti olsun veya olmasın, gebelik oranları üzerinde 
olumlu etkiye sahiptir ve genel kanının aksine luteal faz defekti unifoliküler 
sikluslarda da görülebilmektedir.
Anahtar Kelimeler
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Abstract
Aim: Intrauterine insemination is a widely used technique with advantages 
of being a simple and less invasive method with a lower cost when com-
pared to other assisted reproductive techniques. In the present prospective 
randomized controlled study we aim to prove that progesterone supple-
mentation is a beneficial factor in pregnancies achieved with intra uterine 
insemination and also we want to emphasise that luteal phase deficiency 
does not always occur in multifollicular cycles but can be seen in unifollicular 
cycles as well. Material and Method: Patients diagnosed with unexplained 
infertility between December 2011 and December 2012 were admitted to 
the study group. 278 IUI cycles with COH using recombinant FSH induction 
were recorded. Results: The effect of progesterone supplement on achieving 
pregnancy was statistically significant (p<0.05) with a rate of 33.66% when 
compared to the non-receiving group that had a rate of 12.22%. Discussion: 
Progesterone supplementation, either in defective luteal phase or not has a 
chance of improving pregnancy rates in general and contrary to the notion 
that luteal phase deficiency mainly occurs in multifollicular cycles, it can be 
seen in unifollicular patients as well. 
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Introduction
Intrauterine insemination (IUI) is a widely used technique with 
the benefits of being a simple and less invasive method with 
a lower cost in comparison to other assisted reproductive 
techniques (ART). Patient selection criteria, presence of vari-
ous female infertility factors, differences in methods used for 
ovulation induction and management along with the number 
of cycles and variations in sperm parameters all affect success 
rates of the procedure.
Embryonic implantation occurs in the luteal phase, and a normal 
luteal phase is characterized by a normal hormonal environment, 
normal progesterone (P) secretion by the corpus luteum, and 
an adequate endometrial secretory transformation [1]. Luteal 
phase deficiency can be described as corpus luteum’s deficien-
cy in preparing an adequate endometrial maturity. Therefore 
corpus luteum’s progesterone secretion is critical in achieving 
pregnancy and its healthy progression as long as trophoblastic 
cells are capable of adequate hormone synthesis and secretion 
[2]. Corpus luteum function is dependent on luteinizing hormone 
(LH) stimulation, and LH is dependent on gonadotropin releas-
ing hormone (GnRH) secretion [2-3]. 
Different from natural cycles, controlled ovarian hyperstimu-
lation (COH) often results in multifollicular development with 
higher steroid serum concentrations. LH serum level concentra-
tions are usually low in GnRH agonist COH protocols due to pro-
longed suppression of hypothalamic GnRH secretion which also 
continues to compromise hypopituitaric LH secretion even after 
the stimulation phase, leading to the suggestion that higher se-
rum steroid concentrations might have an adverse affect on LH 
secretion via said feedback mechanisms, which in turn results 
with premature luteolysis leading to corpus luteum deficiency 
and defective P secretion especially in multifollicular cycles [2]. 
In cycles with multifollicular growth, an advanced endometrium 
in the early luteal phase was observed in almost 50% of all pa-
tients [4].
In general it is widely accepted that luteal phase deficiency 
mostly occurs in multifollicular cycles by COH rather than natu-
ral cycles that tend to be unifollicular.
In the present prospective randomized controlled study we aim 
to prove that progesterone supplementation is a beneficial fac-
tor in pregnancies achieved with intra uterine insemination. 
Material and Method
All authors listed state that the protocol for the research project 
has been approved by a suitably constituted Ethics Committee 
of the institution within which the work was undertaken.
All data were recorded in specific study forms and computer as-
signed randomization depending on odd/even number sequence 
for receiving or omitting progesteron supplement at admittance 
was performed. 
All patients were required to fill and sign a specific informed 
consent form detailing the procedure
Patients diagnosed with unexplained infertility in our clinic from 
December 2011 to December 2012 were included in the study 
group. 278 IUI cycles with COH using recombinant follicule 
stimulating hormone (FSH) induction were recorded. 
Patients that were unable to conceive while having regular ovu-
latory mensturations, normal hysterosalphingography (HSG) 
results with bilateral open tubal passage and a normal sperm 
analysis were considered as unexplained infertility. 
Those with previous ovarian surgery, endocrine disorders (thy-
roid disfunctions, hyperprolactinema, polycystic ovarian syn-
drome), obese patients (body mass index above 30) were exclud-
ed from the study group and 87 cycles, that were multifollicular, 
were excluded from the study group as well but continued on 
receiving progesterone, (multifollicular cycles were specifically 
excluded from the study group in order to show if luteal phase 
deficiency occurs also in unifollicular cycles).
Ninety IUI cycles did not receive progesterone supplement of 
which 11 pregnancies were achieved while on the other hand 
101 cycles received progesterone supplement of which 34 preg-
nancies were achieved.
All patients were evaluated by ultrasonography (USG) and basal 
hormone levels on the 2nd day of the cycle before administering 
75 IU of recombinant FSH daily and reevaluated on the 7th day 
with USG. Multifollicular cycles were excluded from the study 
group and after confirming a single follicule of at least 21-22 
mm in diameter, choriongonadotropine 250 µg was adminis-
tered to assure ovulation followed by intra uterine insemina-
tion exactly 36 hours later. Twenty four hours after IUI, 100 mg 
progesterone supplement of thrice a day orally was initiated. 
Since there is no single definitive method for defining luteal 
phase deficiency, laboratory tests measuring P levels at mid-
luteal phase (day 21) before the IUI cycle were obtained none-
theless to support diagnosis.
Patients who had serum progesterone levels of < 6.0 ng/ml 
on day 21 before the IUI cycle were designated to have luteal 
phase deficiency.
As an ethical precaution, patients with low P levels that were 
designated by the computer to “not receive” progesterone were 
omitted from the study group but continued on standard IUI 
protocol receiving P supplement. So in a way, comparison was 
made between both unifollicular groups; one with luteal phase 
deficiency (101 patients) and one with no deficiency (90 pa-
tients) according to day 21 progesterone levels.
Pregnancy was confirmed 12 days after IUI by serum βhCG 
levels, and progesterone supplement was continued until 12th 
week.
Multifollicular cycles continued on their IUI protocol but their 
data was not included in the study.
The primary outcome measures were pregnancy and live birth. 
Efficacy of progesterone supplementation according to com-
parison of pregnancy and live birth rates between treatment 
and control groups were performed by Mann-Whitney U test. A 
P value of < 0.05 was considered to be statistically significant 
and considered as proof of progesterone treatment as a ben-
eficial option in achieving and continuing a healthy pregnancy 
(Table 1).
Results
Eleven pregnancies were achieved in 90 patients that did not 
receive progesterone supplement resulting in a pregnancy rate 
of 12.22% while on the other hand 101 patients received pro-
gesterone supplement of which 34 pregnancies were achieved 
resulting in a pregnancy rate of 33.66%. Live birth rate was 
97.05% for the progesterone receiving group with one case of 
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an anencephalic fetus terminated at 12th week of gestation. 
Live birth rate was 100% for the other group. The effect of 
progesterone supplement on achieving pregnancy was statisti-
cally significant (P = .05) with a rate of 33.66% when compared 
to the non-receiving group that had a rate of 12.22% [Table 1].
Conclusion
Naturally one or two dominant follicules are usually enough for 
the phyisiological feedback mechanism to function properly in 
a healthy woman but various ovulation induction protocols tend 
to produce multifollicules resulting in higher concentrations of 
serum estradiol (E) and progesterone levels thus inhibiting FSH 
and LH secretion causing very low levels of LH synthesis and 
secretion. Inhibin A is also known to have an effect in this, along 
with high E and P levels. 
Lower LH presence is the reason for corpus luteum deficiency 
leading to progesterone deficiency and a shorter luteal phase, 
all of which is in general described as the luteal phase defi-
ciency.
Patients with luteal phase deficiency are known to have fewer 
progesterone receptors on the nuclei of endometrial glandular 
cells therefore this previously mentioned inadequate endome-
trial structure is either because of these fewer receptors or low 
levels of progesterone [5-6].
In light of these evidences describing the physiological mecha-
nisms leading to lower progesterone levels, the simple solution 
of providing the decreased progesterone led us to research the 
subject and deem if it is truly a beneficial treatment option.
Though Erdem, Hamilton and various other authors are sup-
porting progesterone supplementation, authors like Keenan, 
Moghissi and Ebrahimi are against it [7-8]; [9-10]. 
According to our study results we are in favor of progesterone 
supplementation. 
In the material and methods section we mentioned that spe-
cifically unifollicular cycles were chosen for the study group and 
since progesterone usage is the only known treatment for luteal 
phase deficiency, the outcome of the study shows that pregnan-
cy rates were statistically better in the progesterone receiving 
group hence leading us to reason that luteal phase deficiency 
is indirectly proven to be an occurence in both groups, meaning 
also that day 21 progesterone levels is not a definitive method 
in diagnosis and finally since both groups are unifollicular this 
points out that luteal phase defeciency is not dependent on the 
number of follicules in a cycle. 
There is also a debate on the way progesterone is administered. 
While Erdem et al. suggests daily vaginal usage of 90 mg pro-
gesterone gel, Ebrahimi et al. used daily vaginal usage of 400 
mg of progesterone pessaries [8,10]. In our study group we pre-
ferred 100 mg of progesterone tablets orally thrice a day. The 
way progesterone is used is another study subject on the as-
sumption of its benefit on improving 
pregnancy rates. 
In conclusion, even though there are 
many different results obtained from 
various ovulation induction protocols, 
larger study groups involving multiple 
centers are still needed in this re-
search subject to solidify a worldwide 
treatment protocol to be used in as-
sisted reproductive techniques.
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Table 1. Pregnancy Outcome and Rates
Number 
of Cycles
Number of 
Pregnancies
Pregnancy 
Rate [%]*
Number of 
Live Birth
Live Birth 
Rate [%]
Mean BMI Mean day 21 
P levels (ng/ml)
Received 
Progesterone
101 34 33.66* 33 97.05 21.41±4.36 4.41±1.01
Not received 
Progesterone
90 11 12.22* 11 100 26.21±2.11 8.38±1.20
*Mann-Whitney U Test comparing the data between the groups which received or not  received progesterone therapy, P=.05
